| scholarly article | Q13442814 |
| P50 | author | Bengt Glimelius | Q30830855 |
| P2093 | author name string | C Svensson | |
| P O Sjödén | |||
| W Graf | |||
| K Hoffman | |||
| U Haglund | |||
| L K Enander | |||
| R Heuman | |||
| T Linné | |||
| H Sellström | |||
| K Ekström | |||
| P2860 | cites work | The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology | Q29615701 |
| Reporting results of cancer treatment | Q29620070 | ||
| FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer | Q33363249 | ||
| Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Grou | Q33388301 | ||
| Proceedings: A controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer | Q33466760 | ||
| 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer | Q33487198 | ||
| Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer | Q33488159 | ||
| Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer | Q34063503 | ||
| Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer | Q34366342 | ||
| Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public | Q35169442 | ||
| Assessment of response to therapy in advanced breast cancer | Q36068959 | ||
| Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. The Nordic Gastroint | Q39495232 | ||
| Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research | Q41009660 | ||
| Curing gastric cancer--hone the scalpel with magic? | Q42715710 | ||
| Quality of life evaluation by the EORTC questionnaire technique in patients with generalized malignant melanoma on chemotherapy. | Q53633285 | ||
| Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. | Q53647935 | ||
| Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. | Q53667890 | ||
| Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer | Q67762042 | ||
| Chemotherapy of gastric cancer | Q70257764 | ||
| Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group | Q72256279 | ||
| P433 | issue | 2 | |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 163-168 | |
| P577 | publication date | 1997-02-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. | |
| P478 | volume | 8 |
| Q36090039 | (Neo)adjuvant strategies of advanced gastric carcinoma: time for a change? |
| Q35546839 | 18-fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract. |
| Q42281441 | A Case of Long-Term Complete Remission of Advanced Gastric Adenocarcinoma with Liver Metastasis |
| Q49194716 | A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine |
| Q43106885 | A case of gingival candidiasis with bone destruction on gastric cancer patient receiving cytotoxic chemotherapy |
| Q35906916 | A cost-benefit analysis of chemotherapy for gastric cancer |
| Q37449306 | A multi-center, phase ii clinical trial of Padexol (paclitaxel) and cisplatin for patients suffering with advanced gastric cancer |
| Q52682114 | A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer. |
| Q46934937 | A multicentre phase II study of docetaxel plus cisplatin for the treatment of advanced gastric cancer |
| Q37697608 | A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction |
| Q33407672 | A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma |
| Q36564026 | A phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma |
| Q33395721 | A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer |
| Q33366008 | A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients |
| Q44743198 | A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus |
| Q46919249 | A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer |
| Q36614734 | A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer |
| Q36642170 | A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer |
| Q33385867 | A phase II trial of paclitaxel, 5-fluorouracil (5-FU) and cisplatin in patients with metastatic or recurrent gastric cancer |
| Q37341735 | A pilot study of cisplatin, irinotecan, leucovorin and 5-fluorouracil (PILF) combination chemotherapy for advanced gastric cancer |
| Q57805411 | A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study |
| Q38477495 | A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models |
| Q33387432 | A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer |
| Q36858273 | A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer |
| Q57902299 | A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer |
| Q33428751 | A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer |
| Q38204708 | A systematic review of randomized controlled trials testing the efficacy of psychosocial interventions for gastrointestinal cancers. |
| Q43750753 | A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas. |
| Q35768031 | Advanced gastric cancer in jordan from 2004 to 2008: a study of epidemiology and outcomes |
| Q37141665 | Advanced gastric cancer: an update and future directions |
| Q46052234 | Advanced or metastatic gastric cancer in elderly patients: clinicopathological, prognostic factors and treatments |
| Q36798382 | Advances in the treatment of patients with gastric adenocarcinoma. |
| Q30665974 | Alternative methods of interpreting quality of life data in advanced gastrointestinal cancer patients |
| Q93523829 | An Update in Advanced Gastric Cancer: 2009 |
| Q35640101 | Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future |
| Q50146487 | Anticancer therapy for symptom relief? : A systematic review of clinical trials in oncology |
| Q38270899 | Apatinib for the treatment of gastric cancer |
| Q36061780 | Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen |
| Q35005019 | Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy |
| Q51773987 | Benefit of post-operative surveillance for recurrence after curative resection for gastric cancer. |
| Q51048811 | Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. |
| Q34594956 | Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie |
| Q33711626 | CPT-11 in gastrointestinal cancer |
| Q49504289 | CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach |
| Q37475755 | Capecitabine and oxaliplatin (XELOX) for the treatment of patients with metastatic gastric cancer and severe liver dysfunction |
| Q46965182 | Capecitabine and oxaliplatin (XELOX) is safe and effective in patients with advanced gastric cancer |
| Q37136996 | Capecitabine in the treatment of advanced gastric cancer |
| Q38222270 | Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer |
| Q39038994 | Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety |
| Q42571058 | Changes in intracellular redox status influence multidrug resistance in gastric adenocarcinoma cells |
| Q40424672 | Characteristics of Gastric Cancer in Lebanon: a Descriptive Study from a Single Institutional Experience. |
| Q24236634 | Chemotherapy for advanced gastric cancer |
| Q24244040 | Chemotherapy for advanced gastric cancer |
| Q38604012 | Chemotherapy for advanced gastric cancer. |
| Q34617795 | Chemotherapy for advanced gastric cancer: across the years for a standard of care |
| Q37446941 | Chemotherapy for advanced gastric cancer: slow but further progress |
| Q36942475 | Chemotherapy for gastric cancer patients - time for personalization in medicine? |
| Q36398226 | Chemotherapy for gastric cancer. |
| Q26771424 | Chemotherapy in Elderly Patients with Gastric Cancer |
| Q35108798 | Chemotherapy in gastric cancer: a review and updated meta-analysis |
| Q36694149 | Chemotherapy in metastatic gastric cancer: population-based perceptions and practice patterns of medical oncologists |
| Q61868286 | Chemotherapy of oesophago-gastric cancer |
| Q43549952 | Clinical and prognostic significance of coagulation assays in gastric cancer |
| Q83249995 | Clinical outcome of gastric cancer patients with bone marrow metastases |
| Q26828506 | Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach |
| Q27496690 | Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis |
| Q33420157 | Combination Chemotherapy with S-1 and Oxaliplatin (SOX) as First-Line Treatment in Elderly Patients with Advanced Gastric Cancer |
| Q33631546 | Combination chemotherapy with 5-fluorouracil and heptaplatin as first-line treatment in patients with advanced gastric cancer |
| Q43542637 | Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer |
| Q36625990 | Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer |
| Q36551182 | Combination chemotherapy with paclitaxel, cisplatin and fluorouracil for patients with advanced and metastatic gastric or esophagogastric junction adenocarcinoma: a multicenter prospective study |
| Q35948108 | Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer |
| Q49337286 | Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer |
| Q43136050 | Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis |
| Q36042902 | Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 tri |
| Q52562515 | Comparison of efficacy and tolerance between combination therapy and monotherapy as first-line chemotherapy in elderly patients with advanced gastric cancer: Study protocol for a randomized controlled trial. |
| Q55008122 | Comparison of health-related quality of life with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil chemotherapy regimens as first-line systemic therapy in locally advanced inoperable or metastatic gastric or gas |
| Q87515768 | Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel |
| Q38637978 | Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer |
| Q24604411 | Critical appraisal of trastuzumab in treatment of advanced stomach cancer |
| Q37077239 | Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers. |
| Q37181813 | Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction |
| Q26774538 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer |
| Q34413771 | DNA polymerase η protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy |
| Q43162843 | Design of precise third-line therapy for gastric cancer: target or chemotherpy? |
| Q54571851 | Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. |
| Q35181089 | Docetaxel as salvage therapy in highly pretreated and drug resistant gastrointestinal carcinomas |
| Q33386661 | Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens |
| Q36616503 | Docetaxel in the treatment of gastric cancer |
| Q33396506 | Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer |
| Q44136997 | Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study. |
| Q34658209 | Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. |
| Q38563923 | Does surgery have a role in managing incurable gastric cancer? |
| Q28468621 | Effect of oxaliplatin combined with polyenephosphatidylcholine on the proliferation of human gastric cancer SGC-7901 cells |
| Q36644681 | Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer |
| Q37208729 | Efficacy and safety of docetaxel plus oxaliplatin and capecitabine in the first line treatment of advanced gastric adenocarcinoma |
| Q35340883 | Efficacy and safety of oxaliplatin, 5-Fluorouracil, and folinic Acid combination chemotherapy as first-line treatment in metastatic or recurrent gastric cancer |
| Q50285053 | Efficacy and safety study of docetaxel as salvage chemotherapy in metastatic gastric cancer failing fluoropyrimidine and platinum combination chemotherapy |
| Q33411751 | Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial |
| Q47771553 | Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice |
| Q92073891 | Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer |
| Q55338874 | Establishment and validation of prognostic nomograms in first-line metastatic gastric cancer patients. |
| Q40565520 | Etoposide, doxorubicin and cisplatin alternating with 5-fluorouracil, doxorubicin and high-dose methotrexate in patients with advanced adenocarcinoma of the stomach or the gastroesophageal junction |
| Q52223063 | Evaluation of clinical benefit of chemotherapy in patients with upper gastrointestinal cancer. |
| Q40614622 | Evaluation the Survival of Patients with Gastric Cancer Treated with Adjuvant or Palliative Chemotherapy. |
| Q37960206 | Evolving standards of care in advanced gastric cancer |
| Q37362737 | FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. |
| Q43027267 | Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma. |
| Q51256545 | Fibroblast Activation Protein-α-Positive Fibroblasts Promote Gastric Cancer Progression and Resistance to Immune Checkpoint Blockade. |
| Q39728271 | Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Cancer: a Bayesian Network Meta-Analysis. |
| Q79121179 | Follow-Up Surveillance for Recurrence After Curative Gastric Cancer Surgery Lacks Survival Benefit |
| Q34553773 | Gastric adenocarcinoma: review and considerations for future directions |
| Q36327087 | Gastric and gastro-oesophageal cancer therapy |
| Q84276928 | Gastric cancer |
| Q89391950 | Gastric cancer |
| Q99622843 | Gastric cancer |
| Q61963099 | Gastric cancer: past progress and present challenges |
| Q42125510 | Gastric cancer: toward a cisplatin-free disease? |
| Q37697571 | Gastric peritoneal carcinomatosis - a retrospective review |
| Q37522211 | Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study. |
| Q74241859 | Guidelines for the management of oesophageal and gastric cancer |
| Q60923414 | HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells |
| Q47943463 | Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma |
| Q33416606 | Her-2 positive gastric cancer presented with thrombocytopenia and skin involvement: a case report |
| Q53140602 | How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy?. |
| Q37815604 | Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. |
| Q90354330 | Immunotherapy in Advanced Gastric Cancer: An Overview of the Emerging Strategies |
| Q86538059 | Impact of adding cisplatin to S-1 in elderly patients with advanced gastric cancer |
| Q37714449 | Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer |
| Q38447986 | Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer†. |
| Q87885346 | Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution |
| Q33365431 | Infusional 5-fluorouracil and mitomycin C: an effective regimen in the treatment of advanced gastric cancer |
| Q33341264 | Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: a low cost effective regimen |
| Q33828971 | Inhibition of p600 expression suppresses both invasiveness and anoikis resistance of gastric cancer. |
| Q38073827 | Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers |
| Q45154773 | Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study |
| Q33349888 | Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial |
| Q46555285 | Irinotecan plus cisplatin combination against metastatic gastric cancer: phase II study |
| Q33393276 | Irinotecan-involved regimens for advanced gastric cancer: a pooled-analysis of clinical trials |
| Q82044757 | Is there a role for palliative gastrectomy in patients with stage IV gastric cancer? |
| Q53920932 | Jarcho's Syndrome: Bone Marrow Infiltrates from a Gastric Malignancy. |
| Q64076485 | Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach |
| Q41898734 | Latest developments and emerging treatment options in the management of stomach cancer |
| Q48151795 | Liver-directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation. |
| Q47168501 | Long Term Complete Remission in Advanced Gastric Adenocarcinoma With Docetaxel, Oxaliplatin and Capecitabine Combination Regimen. |
| Q43485654 | Long-term outcomes and prognostic factors of patients with advanced gastric cancer treated with S-1 plus cisplatin combination chemotherapy as a first-line treatment |
| Q42285544 | Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial |
| Q46966919 | Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology |
| Q83969774 | Longterm survival of a Western patient with metastatic gastric cancer treated with S-1 plus cisplatin |
| Q37642780 | ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer |
| Q36891375 | Management of gastric adenocarcinoma |
| Q34175118 | Management of upper gastrointestinal cancers |
| Q36644664 | Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial |
| Q37181422 | Measuring patient-reported outcomes in advanced gastric cancer |
| Q61868280 | Medical management of advanced gastric cancer |
| Q38995616 | MicroRNA-21 contributes to the discrimination of chemoresistance in metastatic gastric cancer |
| Q33413448 | Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study |
| Q33375019 | Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study |
| Q43872716 | Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC). |
| Q64097970 | Modified Epirubicin, cisplatin, and 5-FU regimen as first-line chemotherapy in metastatic gastric or gastroesophageal junction adenocarcinoma: A Phase II study |
| Q35340865 | Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer. |
| Q33410627 | Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study |
| Q49945586 | Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06). |
| Q33372119 | Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. |
| Q40265325 | Multiparametric fully-integrated 18-FDG PET/MRI of advanced gastric cancer for prediction of chemotherapy response: a preliminary study |
| Q59136693 | New drug developments in metastatic gastric cancer |
| Q43112721 | New perspectives in the treatment of advanced or metastatic gastric cancer |
| Q41135814 | Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients |
| Q47992739 | Nonpalliative surgical resection for gastric cancer patients with distant metastasis |
| Q37494644 | Novel investigational drugs for gastric cancer |
| Q37566645 | Novel targets in esophageal and gastric cancer: beyond antiangiogenesis |
| Q38139297 | Optimal chemotherapy for advanced gastric cancer: is there a global consensus? |
| Q46255877 | Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study |
| Q30719628 | Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan |
| Q33389036 | Outcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis |
| Q36536982 | Outcomes of third-line docetaxel-based chemotherapy in advanced gastric cancer who failed previous oxaliplatin-based and irinotecan-based chemotherapies |
| Q37336375 | Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer |
| Q33766456 | Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) combination chemotherapy as a salvage treatment in advanced gastric cancer |
| Q34783589 | Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy |
| Q34670947 | Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer |
| Q33778285 | Paclitaxel combined with capecitabine as first-line chemotherapy for advanced or recurrent gastric cancer |
| Q33356984 | Paclitaxel, carboplatin, and oral etoposide in advanced gastric adenocarcinoma: association with severe myelotoxicity |
| Q33728364 | Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients |
| Q34402165 | Palliative care research |
| Q35936039 | Palliative chemotherapy for advanced gastric cancer |
| Q35534052 | Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg |
| Q36516605 | Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction foll |
| Q33204551 | Palliative treatment options for esophageal and gastric cancer |
| Q36661984 | Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. |
| Q53213677 | Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility? |
| Q46681927 | Performance of outpatient regimen of S-1 in combination with fractional cisplatin for advanced or recurrent gastric cancers: a phase I study |
| Q38842137 | Personalised Treatment in Gastric Cancer: Myth or Reality? |
| Q37011966 | Pharmacotherapy for oesophagogastric cancer. |
| Q24810562 | Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer |
| Q85026066 | Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer |
| Q42863444 | Phase I study of Paclitaxel, Cisplatin and 5-fluorouracil combination chemotherapy for unresectable / recurrent gastric cancer |
| Q36611262 | Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. |
| Q43080282 | Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer. |
| Q36977421 | Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma |
| Q34507843 | Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma |
| Q33407676 | Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer |
| Q60697885 | Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients |
| Q36614109 | Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer |
| Q36615597 | Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma |
| Q46822414 | Phase I/II study of a combination of S-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer |
| Q35949510 | Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer |
| Q33435898 | Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma |
| Q46707260 | Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002). |
| Q33364558 | Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy |
| Q33374960 | Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer |
| Q37336356 | Phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with recurrent or metastatic gastric cancer |
| Q37222473 | Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer |
| Q42986070 | Phase II study of oxaliplatin, UFT, and leucovorin in patients with metastatic gastric cancer |
| Q36853997 | Phase II study of paclitaxel, cisplatin, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer |
| Q42032242 | Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer |
| Q33389519 | Phase II study of sunitinib as second-line treatment for advanced gastric cancer |
| Q53458025 | Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer. |
| Q36615060 | Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. |
| Q83782142 | Phase II study of weekly paclitaxel, cisplatin, and 5-fluorouracil for advanced gastric cancer |
| Q35037527 | Placebo effects in oncology |
| Q37651342 | Postgastrectomy follow-up in the West: evidence base, guidelines, and daily practice |
| Q64108311 | Prediction of Treatment Outcome of Chemotherapy Using Perfusion Computed Tomography in Patients with Unresectable Advanced Gastric Cancer |
| Q42323722 | Preliminary trial of adjuvant surgery for advanced gastric cancer |
| Q41889228 | Preliminary trial of surgery after chemotherapy for advanced gastric cancer with peritoneal dissemination |
| Q36791086 | Primary extraosseous Ewing sarcoma of the lung in children |
| Q41242339 | Profiling chemotherapy-associated myelotoxicity among Chinese gastric cancer population receiving cytotoxic conventional regimens: epidemiological features, timing, predictors and clinical impacts |
| Q51046395 | Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer. |
| Q41718964 | Prognostic factors in patients with loco-regionally advanced gastric cancer |
| Q35661060 | Prognostic factors of second and third line chemotherapy using 5-fu with platinum, irinotecan, and taxane for advanced gastric cancer |
| Q37197679 | Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis |
| Q43206575 | Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer |
| Q33430940 | Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer |
| Q33357849 | Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study |
| Q35045572 | Quality of life in gastric cancer |
| Q48083144 | Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin). |
| Q36720792 | Quality of life in patients with oesophageal and gastric cancer: an overview |
| Q40060365 | Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer |
| Q34569928 | Quality-of-life assessment in palliative care |
| Q44066036 | Ralitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on quality of life, patients' preferences and health economics |
| Q36616011 | Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer |
| Q35927364 | Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. |
| Q34584724 | Randomized clinical trials in gastric cancer |
| Q42915836 | Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial |
| Q36065419 | Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer |
| Q40032426 | Randomized phase III trial of cisplatin, epirubicin, leucovorin, 5-fluorouracil (PELF) combination versus 5-fluorouracil alone as adjuvant chemotherapy in curative resected stage III gastric cancer |
| Q36376439 | Recent developments in the systemic therapy of advanced gastroesophageal malignancies |
| Q34590788 | Recent developments in the treatment of gastric carcinoma |
| Q35445166 | Refining docetaxel-containing therapy for gastric cancer. |
| Q36615965 | Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. |
| Q48145007 | Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review. |
| Q33729150 | Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer |
| Q45784055 | Retrospective analysis of docetaxel, oxaliplatin plus fluorouracil compared with epirubicin, cisplatin and fluorouracil as first-line therapy for advanced gastric cancer |
| Q79291006 | Retrospective analysis of stage IV advanced gastric cancer treated with S-1 or other chemotherapy |
| Q53665182 | Retrospective evaluation of the efficacy of first-line treatment of advanced gastric cancer with docetaxel and oxaliplatin. |
| Q59134275 | Retrospective study of oxaliplatin, leucovarin and 5 fluoruracil regimen in patients with advanced gastric cancer with poor performance status: A study at a tertiary center of South India |
| Q35081966 | S-1-based therapy versus S-1 monotherapy in advanced gastric cancer: a meta-analysis |
| Q42364212 | Safe use of capecitabine-cisplatin in metastatic gastric carcinoma with severe liver dysfunction: a case report from Algeria |
| Q46708594 | Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer. |
| Q33366124 | Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer |
| Q52586997 | Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan. |
| Q37992841 | Second-line chemotherapy for advanced gastric cancer in Korea |
| Q38750633 | Second-line chemotherapy for patients with advanced gastric cancer. |
| Q36964966 | Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? |
| Q84735449 | Second-line chemotherapy with paclitaxel and doxifluridine after failure of S-1 in elderly patients with unresectable advanced or recurrent gastric cancer |
| Q36842786 | Second-line therapy for esophageal cancer |
| Q26778027 | Second-line treatment of metastatic gastric cancer: Current options and future directions |
| Q44665743 | Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy |
| Q60932024 | Should S-1 be better than capecitabine for patients with advanced gastric cancer in Asia? A systematic review and meta-analysis |
| Q44681408 | Significance of palliative gastrectomy for late-stage gastric cancer patients |
| Q35095365 | Status of treatment for advanced gastric carcinoma |
| Q24246675 | Supportive care for patients with gastrointestinal cancer |
| Q90321326 | Surgical management of metastatic gastric cancer: moving beyond the guidelines |
| Q39234296 | Survival after failure of first-line chemotherapy in advanced gastric cancer patients: differences between Japan and the rest of the world |
| Q92617822 | Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review |
| Q44012763 | Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912. |
| Q47246118 | Synergistic Effect of Forbesione From Garcinia hanburyi in Combination with 5-Fluorouracil on Cholangiocarcinoma |
| Q64100306 | Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer |
| Q35000785 | Targeting metastatic upper gastrointestinal adenocarcinomas |
| Q38741697 | Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall? |
| Q51812919 | Thalidomide combined with chemotherapy in treating elderly patients with advanced gastric cancer. |
| Q94526793 | The Prognostic Value of Neutrophil-to-lymphocyte Ratio and Monocyte-to-lymphocyte Ratio in Metastatic Gastric Cancer Treated with Systemic Chemotherapy |
| Q42930809 | The addition of pravastatin to chemotherapy in advanced gastric carcinoma: A randomised phase II trial |
| Q37400028 | The changing use of palliative chemotherapy for recurrent esophagogastric cancer: a single center retrospective 15-year review. |
| Q98288459 | The combination of Biochanin A and SB590885 potentiates the inhibition of tumour progression in hepatocellular carcinoma |
| Q40383915 | The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma |
| Q33746810 | The efficacy of docetaxel and cisplatin combination chemotherapy for the treatment of advanced gastric cancer after failing to 5-fluorouracil based chemotherapy |
| Q33437413 | The efficiency and safety of trastuzumab for advanced gastric and gastroesophageal cancer: a meta-analysis of five randomized controlled trials |
| Q35139161 | The role of chemotherapy in the current treatment of gastric cancer |
| Q53521867 | The standard of reporting of health-related quality of life in clinical cancer trials. |
| Q50650462 | The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy. |
| Q46817815 | The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma. |
| Q33818002 | Third-line chemotherapy in advanced gastric cancer: A systematic review and meta-analysis |
| Q42827455 | Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis. |
| Q38467530 | Three-week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer: a retrospective study with 159 patients |
| Q43193739 | Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer |
| Q34494063 | Three-weekly s-1 monotherapy as first-line treatment in elderly patients with recurrent or metastatic gastric cancer |
| Q33903541 | Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel |
| Q37633540 | Trastuzumab for gastric cancer |
| Q27851578 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial |
| Q90749501 | Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer |
| Q44003311 | Treatment of advanced gastric cancer with etoposide, folinic acid, and fluorouracil in the clinical setting: efficacy of therapy and value of serum tumor markers. |
| Q77668171 | Treatment of advanced gastric cancer with oral etoposide, leucovorin and tegafur: experience with an oral modification of the etoposide, leucovorin and 5-fluorouracil (ELF) regimen |
| Q41196535 | Treatment of lymph node metastases from gastric cancer with a combination of Irreversible Electroporation and Electrochemotherapy: a case report |
| Q35060178 | Treatment of stage IV gastric cancer with induction chemotherapy using S-1 and cisplatin followed by curative resection in selected patients |
| Q34661367 | Treatment options in patients with metastatic gastric cancer: current status and future perspectives |
| Q55379237 | Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study. |
| Q40315009 | Weekly Taxotere and cisplatin with continuous-infusion 5-fluoruracil for the treatment of advanced gastric and esophageal cancer: a prospective, observational, single-institution experience. |
| Q36292847 | Weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin: an effective chemotherapy in advanced gastric cancer |
| Q39682966 | What is the reference cytotoxic regimen for advanced gastric cancer: standard versus optimal therapy? |
Search more.